极早产儿先天性肾上腺皮质增生症21-羟化酶缺乏症1例并文献复习
One Case of Congenital Adrenal Hyperplasia 21-Hydroxylase Deficiency in Very Premature Infants and Literature Review
摘要: 目的:报道1例胎龄28周 + 3天起病、CYP21A2基因变异导致的经典型先天性肾上腺皮质增生症。探讨该病的早期诊断及经验分享。方法:回顾青岛大学附属医院新生儿科收治的胎龄28周 + 3天极早产儿先天性肾上腺皮质增生症21-羟化酶缺乏症1例,并复习相关文献。结果:患儿系胎龄28周 + 3天出生的极早产儿,以全身皮肤色深、外阴肥大、色素沉着为主要临床表现,合并严重低钠血症和高钾血症,足跟血筛查17-羟孕酮244 nmol/L,外送激素示17-羟孕酮29.63 ng/ml,21-脱氧皮质醇17661.1 pg/mL。予氢化可的松、9-α氟氢可的松及口服氯化钠等治疗,好转出院。患儿高通量全外显子组基因检测显示CYP21A2基因突变,家系验证变异分别来自患儿父母。结论:不同于足月新生儿,早产儿因其特殊性,利用17-羟孕酮对21-羟化酶缺乏症进行早期诊断有一定难度,容易漏诊或误诊,21-脱氧皮质醇可能是比17-羟孕酮更特异的21-羟化酶缺乏症标志物。
Abstract: Objective: To report a case of classical congenital adrenal hyperplasia caused by CYP21A2 gene mutation at 28 weeks + 3 days of gestational age. To explore the early diagnosis and experience sharing of the disease. Methods: A case of congenital adrenal hyperplasia 21-hydroxylase deficiency in very premature infants with gestational age of 28 weeks + 3 days admitted to the Department of Neonatology, Affiliated Hospital of Qingdao University was reviewed and related literatures were reviewed. Results: The patient was a very premature infant born at 28 weeks + 3 days of gestational age. The main clinical manifestations were deep skin color, vulval hypertrophy and pigmentation. Severe hyponatremia and hyperkalemia were combined. Heel blood screening showed 244 nmol/L of 17-hydroxyprogesterone, 29.63 ng/ml of 17-hydroxyprogesterone and 17661.1 pg/mL of 21-deoxycorticosteroid. The patient was treated with hydrocortisone, 9-α fludrocortisone and oral sodium chloride, and was discharged after improvement. High-throughput whole exome gene detection showed CYP21A2 gene mutation in the child, and the family verification variation was from the parents of the child. Conclusion: Different from full-term neonates, it is difficult to use 17-hydroxyprogesterone for early diagnosis of 21-hydroxylase deficiency in premature infants due to its particularity, which is easy to be missed or misdiagnosed. 21-deoxycorticosteroid may be a more specific marker of 21-hydroxylase deficiency than 17-hydroxyprogesterone.
文章引用:邵涵, 李向红, 马丽丽. 极早产儿先天性肾上腺皮质增生症21-羟化酶缺乏症1例并文献复习[J]. 临床医学进展, 2025, 15(7): 663-668. https://doi.org/10.12677/acm.2025.1572037

参考文献

[1] El-Maouche, D., Arlt, W. and Merke, D.P. (2017) Congenital Adrenal Hyperplasia. The Lancet, 390, 2194-2210. [Google Scholar] [CrossRef] [PubMed]
[2] Merke, D.P. and Auchus, R.J. (2020) Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. New England Journal of Medicine, 383, 1248-1261. [Google Scholar] [CrossRef] [PubMed]
[3] Claahsen-van der Grinten, H.L., Speiser, P.W., Ahmed, S.F., Arlt, W., Auchus, R.J., Falhammar, H., et al. (2021) Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management. Endocrine Reviews, 43, 91-159. [Google Scholar] [CrossRef] [PubMed]
[4] Speiser, P.W., Azziz, R., Baskin, L.S., Ghizzoni, L., Hensle, T.W., Merke, D.P., et al. (2010) Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 95, 4133-4160. [Google Scholar] [CrossRef] [PubMed]
[5] Speiser, P.W., Arlt, W., Auchus, R.J., Baskin, L.S., Conway, G.S., Merke, D.P., et al. (2018) Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 103, 4043-4088. [Google Scholar] [CrossRef] [PubMed]
[6] Reisch, N., Taylor, A.E., Nogueira, E.F., Asby, D.J., Dhir, V., Berry, A., et al. (2019) Alternative Pathway Androgen Biosynthesis and Human Fetal Female Virilization. Proceedings of the National Academy of Sciences, 116, 22294-22299. [Google Scholar] [CrossRef] [PubMed]
[7] Kamrath, C., Hochberg, Z., Hartmann, M.F., Remer, T. and Wudy, S.A. (2012) Increased Activation of the Alternative “Backdoor” Pathway in Patients with 21-Hydroxylase Deficiency: Evidence from Urinary Steroid Hormone Analysis. The Journal of Clinical Endocrinology & Metabolism, 97, E367-E375. [Google Scholar] [CrossRef] [PubMed]
[8] Miller, W.L. (2019) Congenital Adrenal Hyperplasia: Time to Replace 17OHP with 21-Deoxycortisol. Hormone Research in Paediatrics, 91, 416-420. [Google Scholar] [CrossRef] [PubMed]
[9] New, M.I., Abraham, M., Gonzalez, B., Dumic, M., Razzaghy-Azar, M., Chitayat, D., et al. (2013) Genotype-Phenotype Correlation in 1,507 Families with Congenital Adrenal Hyperplasia Owing to 21-Hydroxylase Deficiency. Proceedings of the National Academy of Sciences, 110, 2611-2616. [Google Scholar] [CrossRef] [PubMed]
[10] Riedl, S., Röhl, F., Bonfig, W., Brämswig, J., Richter-Unruh, A., Fricke-Otto, S., et al. (2019) Genotype/Phenotype Correlations in 538 Congenital Adrenal Hyperplasia Patients from Germany and Austria: Discordances in Milder Genotypes and in Screened versus Prescreening Patients. Endocrine Connections, 8, 86-94. [Google Scholar] [CrossRef] [PubMed]
[11] Krone, N., Rose, I.T., Willis, D.S., Hodson, J., Wild, S.H., Doherty, E.J., et al. (2013) Genotype-Phenotype Correlation in 153 Adult Patients with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency: Analysis of the United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (Cahase) Cohort. The Journal of Clinical Endocrinology & Metabolism, 98, E346-E354. [Google Scholar] [CrossRef] [PubMed]
[12] Odenwald, B., Nennstiel-Ratzel, U., Dörr, H., Schmidt, H., Wildner, M. and Bonfig, W. (2016) Children with Classic Congenital Adrenal Hyperplasia Experience Salt Loss and Hypoglycemia: Evaluation of Adrenal Crises during the First 6 Years of Life. European Journal of Endocrinology, 174, 177-186. [Google Scholar] [CrossRef] [PubMed]
[13] Bonfig, W. (2017) Growth and Development in Children with Classic Congenital Adrenal Hyperplasia. Current Opinion in Endocrinology, Diabetes & Obesity, 24, 39-42. [Google Scholar] [CrossRef] [PubMed]
[14] Fraga, N.R., Minaeian, N. and Kim, M.S. (2024) Congenital Adrenal Hyperplasia. Pediatrics in Review, 45, 74-84. [Google Scholar] [CrossRef] [PubMed]
[15] Witchel, S.F. (2019) Newborn Screening for Congenital Adrenal Hyperplasia: Beyond 17-Hydroxyprogesterone Concentrations. Jornal de Pediatria, 95, 257-259. [Google Scholar] [CrossRef] [PubMed]
[16] Jiang, X., Tang, F., Feng, Y., Li, B., Jia, X., Tang, C., et al. (2019) The Adjustment of 17-Hydroxyprogesterone Cut-Off Values for Congenital Adrenal Hyperplasia Neonatal Screening by GSP According to Gestational Age and Age at Sampling. Journal of Pediatric Endocrinology and Metabolism, 32, 1253-1258. [Google Scholar] [CrossRef] [PubMed]
[17] Gidlöf, S., Wedell, A., Guthenberg, C., von Döbeln, U. and Nordenström, A. (2014) Nationwide Neonatal Screening for Congenital Adrenal Hyperplasia in Sweden: A 26-Year Longitudinal Prospective Population-Based Study. JAMA Pediatrics, 168, Article No. 567. [Google Scholar] [CrossRef] [PubMed]
[18] Gatelais, F., Berthelot, J., Beringue, F., Descamps, P., Bonneau, D., Limal, J., et al. (2004) Effect of Single and Multiple Courses of Prenatal Corticosteroids on 17-Hydroxyprogesterone Levels: Implication for Neonatal Screening of Congenital Adrenal Hyperplasia. Pediatric Research, 56, 701-705. [Google Scholar] [CrossRef] [PubMed]
[19] Hayashi, G.Y., Carvalho, D.F., de Miranda, M.C., Faure, C., Vallejos, C., Brito, V.N., et al. (2017) Neonatal 17‐Hydroxyprogesterone Levels Adjusted According to Age at Sample Collection and Birthweight Improve the Efficacy of Congenital Adrenal Hyperplasia Newborn Screening. Clinical Endocrinology, 86, 480-487. [Google Scholar] [CrossRef] [PubMed]
[20] Mendoza-Rojas, V.C., Díaz-Martínez, L.A., Mantilla-Mora, G., Contreras-García, G.A., Mora-Bautista, V.M., Martínez-Paredes, J.F., et al. (2017) Valores de 17-hidroxiprogesterona en recién nacidos prematuros sanos. Colombia Medica, 48, 161-166. [Google Scholar] [CrossRef
[21] Held, P.K., Bialk, E.R., Lasarev, M.R. and Allen, D.B. (2022) 21-Deoxycortisol Is a Key Screening Marker for 21-Hydroxylase Deficiency. The Journal of Pediatrics, 242, 213-219.e1. [Google Scholar] [CrossRef] [PubMed]
[22] Watanabe, K., Tsuji-Hosokawa, A., Hashimoto, A., Konishi, K., Ishige, N., Yajima, H., et al. (2022) The High Relevance of 21-Deoxycortisol, (Androstenedione + 17α-Hydroxyprogesterone)/Cortisol, and 11-Deoxycortisol/17α-Hydroxyprogesterone for Newborn Screening of 21-Hydroxylase Deficiency. The Journal of Clinical Endocrinology & Metabolism, 107, 3341-3352. [Google Scholar] [CrossRef] [PubMed]